|
1
|
Lichtman MA, Beutler E, Thomas JK,
Seligsohn U, Kaushansky K and Josef TP: Inflammatory and malignant
histiocytosis. In: Williams Hematology. 7th edition. McGraw-Hill
Book Co., New York, pp993-1007, 2005.
|
|
2
|
Jordan MB and Filipovich AH: Histiocytic
disorders. In: Basic Principles and practice. 6th edition.
Elsevier, Philadelphia, PA, pp686-700, 2013.
|
|
3
|
Mosser DM and Edwards JP: Exploring the
full spectrum of macrophage activation. Nat Rev Immunol. 8:958–969.
2008.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Szyper-Kravitz A and Martine M: The
hemophagocytic syndrome/macrophage activation syndrome: A final
common pathway of a cytokine storm. Isr Med Assoc J. 11:633–634.
2009.PubMed/NCBI
|
|
5
|
Grom AA and Alexei A: Macrophage
activation syndrome, a review of diagnosis, treatment, and
prognosis. Rheumatologist. 4:22–30. 2012.
|
|
6
|
Sawhney S, Woo P and Murray K: Macrophage
activation syndrome: A potentially fatal complication of rheumatic
disorders. Arch Dis Child. 85:421–426. 2001.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Athreya BH: Is macrophage activation
syndrome a new entity? Clin Exp Rheumatol. 20:121–123.
2002.PubMed/NCBI
|
|
8
|
Villanueva J, Lee S, Giannini EH, Graham
TB, Passo MH, Filipovich A and Grom AA: Natural killer cell
dysfunction is a distinguishing feature of systemic onset juvenile
rheumatoid arthritis and macrophage activation syndrome. Arthritis
Res Ther. 7:30–37. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
9
|
Grom AA: Natural killer cell dysfunction:
A common pathway in systemic-onset juvenile rheumatoid arthritis,
macrophageactivation syndrome, and hemophagocytic
lymphohistiocytosis? Arthritis Rheum. 50:689–698. 2004.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Canna SW and Behrens EM: Making sense of
the cytokine storm: A conceptual framework for understanding,
diagnosing, and treating hemophagocytic syndromes. Pediatr Clin
North Am. 59:329–344. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Dapena DJL, Díaz de Heredia RC, Bastida
VP, Llort SA, Elorza AI, Olivé OT and De Toledo CJS:
Haemophagocytic syndrome: A common pathogenic mechanism of various
aetiologies. An Pediatr. 71:110–116. 2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Odegaard JI and Chawla A: Alternative
macrophage activation and metabolism. Annu Rev Pathol. 6:275–297.
2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Strippoli R, Carvello F, Scianaro R, De
Pasquale L, Vivarelli M, Petrini S, Bracci-Laudiero L and De
Benedetti F: Amplification of the response to Toll-like receptor
ligands by prolonged exposure to interleukin-6 in mice: Implication
for the pathogenesis of macrophage activation syndrome. Arthritis
Rheum. 64:1680–1688. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Behrens EM, Canna SW, Slade K, Rao S,
Kreiger PA, Paessler M, Kambayashi T and Koretzky GA: Repeated TLR9
stimulation results in macrophage activation syndrome-like disease
in mice. J Clin Invest. 121:2264–2277. 2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Grom AA, Villanueva J, Lee S, Goldmuntz
EA, Passo MH and Filipovich A: Natural killer cell dysfunction in
patients with systemic-onset juvenile rheumatoid arthritis and
macrophage activation syndrome. J Pediatr. 142:292–296.
2003.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Clementi R, Emi L, Maccario R, Liotta F,
Moretta L, Danesino C and Arico M: Adult onset and atypical
presentation of hemophagocytic lymphohistiocytosis in siblings
carrying PRF1 mutations. Blood. 100:2266–2267. 2002.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bracaglia C, Prencipe G and De Benedetti
F: Macrophage activation syndrome: Different mechanisms leading to
a one clinical syndrome. Pediatr Rheumatol Online J.
15(5)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Stephan JL, Zeller J and Hubert P:
Macrophage activation syndrome and rheumatic disease in childhood:
A report of four new cases. Clin Exp Rheumatol. 11:451–456.
1993.PubMed/NCBI
|
|
19
|
You CR, Kim HR, Yoon CH, Lee SH, Park SH
and Kim HY: Macrophage activation syndrome in juvenile rheumatoid
arthritis successfully treated with cyclosporine A: A case report.
J Korean Med Sci. 21:1124–1127. 2006.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kelly A and Ramanan AV: Recognition and
management of macrophage activation syndrome in juvenile
arthrititis. Curr Opin Rheumatol. 9:477–481. 2007.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Deane S, Selmi C, Teuber SS and Gershwin
ME: Macrophage activation syndrome in autoimmune disease. Int Arch
Allergy Immunol. 153:109–120. 2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Bennett TD, Fluchel M, Hersh AO, Hayward
KN, Hersh AL, Brogan TV, Srivastava R, Stone BL, Korgensky EK,
Mundorff MB, et al: Macrophage activation syndrome in children with
systemic lupus erythematosus and children with juvenile idiopathic
arthritis. Arthritis Rheum. 64:4135–4142. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Shafferman A, Birmingham JD and Cron RQ:
High dose anakinra for treatment ofsevere neonatal Kawasaki
disease: A case report. Pediatr Rheumatol Online J. 11:12–26.
2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Egües DCA, Uriarte EM, Meneses VC,
Aldasoro CV, Hernando RI and Belzunegui OJ: Hemophagocytic syndrome
as the initialmanifestation of systemic lupus erythematosus.
Reumatol Clin. 10:321–324. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Vishwanath VK, Krishnamurthy A, Karyampudi
A and Dutta TK: Fever of unknown origin in a patient of systemic
onset juvenile idiopathic arthritis. Indian J Med Sci. 64:333–336.
2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Young LR, Borchers MT, Allen HL, Gibbons
RS and McCormack FX: Lung-restricted macrophage activation in the
pearl mouse model of Hermansky-Pudlak syndrome. J Immunol.
176:4361–4368. 2006.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hur M, Kim YC, Lee KM and Kim KN:
Macrophage activation syndrome in a child with systemic juvenile
rheumatoid arthritis. J Korean Med Sci. 20:695–698. 2005.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Boca AN, Talamonti M, Galluzzo M, Botti E,
Vesa SC, Chimenti S, Buzoianu AD and Costanzo A: Genetic variations
in ILB decreasing the risk for psoriasis. Immunol Lett.
156:127–131. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Liu AC, Yang Y, Li MT, Jia Y, Chen S, Ye
S, Zeng XZ, Wang Z, Zhao JX, Liu XY, et al: Macrophage activation
syndrome in systemic lupus erythematosus: A multicenter,
case-control study in China. Clin Rheumatol. 37:93–100.
2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Cascio A, Pernice LM, Barberi G, Delfino
D, Biondo C, Beninati C, Mancuso G, Morales AJR and Iaria C:
Secondary hemophagocytic lymphohistiocytosis in zoonoses. A
systematic review. Eur Rev Med Pharmacol Sci. 16:1324–1337.
2012.PubMed/NCBI
|
|
31
|
Ruiz GMA, Ruiz JA, Menéndez GJL, Pérez
CAM, Domínguez MS and Rodríguez EF: Visceral leishmaniasis and
bronchial asthma: Influence of steroid therapy in the development
of the macrophage activation syndrome and relative adrenal
insufficiency. An Med Interna. 25:279–283. 2008.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Soldo-Juresa D, Radman M, Pejsa V and
Bozikov V: Reactive macrophage activation syndrome in a patient
with parvovirus B19 infection, lymphocytic lichenoid vasculitis,
urticaria and angioedema. Ann Saudi Med. 30:88–89. 2010.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chellapandian D, Das R, Zelley K, Wiener
SJ, Zhao H, Teachey DT and Nichols KE: EBV-HLH Rituximab Study
Group. Treatment of Epstein Barr virus-induced haemophagocytic
lymphohistiocytosis with rituximab-containing chemo
immunotherapeutic regimens. Br J Haematol. 162:376–382.
2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Stabile A, Bertoni B, Ansuini V, La
Torraca I, Salli A and Rigante D: The clinical spectrum and
treatment options of macrophage activation syndrome in the
pediatric age. Eur Rev Med Pharmacol Sci. 10:53–59. 2006.PubMed/NCBI
|
|
35
|
Kuppe C, Westphal S, Bücher E, Moeller MJ,
Heintz B, Schneider ME and Floege J: Macrophage activation syndrome
in a patient with pulmonary inflammatory myofibroblastic tumour.
Allergy Asthma Clin Immunol. 8(6)2012.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ravelli A: Macrophage activation syndrome.
Curr Opp Rheum. 14:548–552. 2002.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Souabni L, Dridi L, Ben AK, Kassab S,
Chekili S, Laater A and Zakraoui L: Possible macrophage activation
syndrome following initiation of adalimumab in a patient with
adult-onset Still's disease. Pan Afr Med J. 17(94)2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ikegawa T, Yamazaki K, Nishimura K,
Kanetaka T, Kikuchi M, Nozawa T, Hara R, Sato T, Sakurai N and
Yokota S: A case of severe systemic juvenile idiopathic arthritis
introduced tocilizumab in early phase of the disease. Nihon
RinshoMeneki Gakkai Kaishi. 37:176–182. 2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Delavigne K, Bérard E, Bertoli S, Corre J,
Duchayne E, Demur C, De Mas VM, Borel C, Picard M, Alvarez M, et
al: Hemophagocytic syndrome in patients with acute myeloid leukemia
undergoing intensive chemotherapy. Haematologica. 99:474–480.
2014.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Sandhu C, Chesney A, Piliotis E, Buckstein
R and Koren S: Macrophage activation syndrome after etanercept
treatment. J Rheumatol. 34:241–242. 2007.PubMed/NCBI
|
|
41
|
Teachey DT, Rheingold SR, Maude SL,
Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M,
Berg RA, et al: Cytokine release syndrome after blinatumomab
treatment related to abnormal macrophage activation and ameliorated
with cytokine-directed therapy. Blood. 121:5154–5157.
2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Leslye FC, Aedo PK and Miraval-Niño de
Guzmán T: Macrophage activation syndrome: Experience in the
questioned role of etoposide. Reumatol Clin. 13:239–240.
2017.PubMed/NCBI View Article : Google Scholar : (In English,
Spanish).
|
|
43
|
Hadchouel M, Prieur AM and Griscelli C:
Acute hemorrhagic, hepatic, and neurologic manifestations in
juvenile rheumatoid arthritis: Possible relationship to drugs or
infection. J Pediatr. 106:561–566. 1985.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Janka G and Zur Stadt U: Familial and
acquired hemophagocytic lymphohistiocytosis. Hematology Am Soc
Hematol Educ Program. 82–88. 2005.PubMed/NCBI View Article : Google Scholar : doi:
10.1182/asheducation-2005.1.82.
|
|
45
|
Ramanan AV and Baildam EM: Macrophage
activation syndrome is hemophagocytic lymphohistiocytosis-need for
the right terminology. J Rheumatol. 29(1105)2002.PubMed/NCBI
|
|
46
|
Haque SF: Macrophage activation syndrome.
Med Update. 7(447)2011.
|
|
47
|
Davì S, Lattanzi B, Demirkaya E, Rosina S,
Bracciolini S, Novelli A, Ruperto N, Martini A, Cron R and Ravelli
A: Toward the development of new diagnostic criteria for Macrophage
activation syndrome in Systemic juvenile idiopathic arthritis. Ann
Paediatr Rheum. 1:1–7. 2012.
|
|
48
|
Grom AA: Macrophage activation syndrome
and reactive hemophagocytic lymphohistiocytosis: The same entities?
Curr Opin Rheumatol. 15:587–590. 2003.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Ramanan AV and Schneider R: Macrophage
activation syndrome-what's in a name! J Rheumatol. 30:251–253.
2003.PubMed/NCBI
|
|
50
|
Ravelli A, Magni-Manzoni S, Pistorio A,
Besana C, Foti T, Ruperto N, Viola S and Martini A: Preliminary
diagnostic guidelines for macrophage activation syndrome
complicating systemic juvenile diopathic arthritis. Pediatr.
146:598–604. 2005.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Emmenegger U, Schaer DJ, Larroche C and
Neftel KA: Haemophagocytic syndromes in adults: Current concepts
and challenges ahead. Swiss Med Wkly. 135:299–314. 2005.PubMed/NCBI
|
|
52
|
Feldmann J, Callebaut I and Raposo G: Munc
13-4 is essential for cytolytic granules fusion and is mutated on a
form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell.
115:461–473. 2003.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Rosado FG and Kim AS: Hemophagocytic
lymphohistiocytosis: An update on diagnosis and pathogenesis. Am J
Clin Pathol. 139:713–727. 2013.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Stephan J, Kone-Paut I, Galambrun C, Mouy
R, Bader-Meunier B and Prieur A: Reactive haemophagocytic syndrome
in children with inflammatory disorders: A retrospective study of
24 patients. Rheumatology. 40:1285–1292. 2001.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Canna SW and Behrens EM: Not all
hemophagocytes are created equally: Appreciating the heterogeneity
of the hemophagocytic syndromes. Curr Opin Rheumatol. 24:113–118.
2012.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Bode FN, Ammann S, Al-Herz W, Bataneant M,
Dvorak CC, Gehring S, Gennery A, Gilmour KC, Gonzalez-Granado LI,
Groß-Wieltsch U, et al: The syndrome of hemophagocytic
lymphohistiocytosis in primary immunodeficiencies: Implications for
differential diagnosis and pathogenesis. Haematologica.
100:978–988. 2015.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Lenghel LM, Baciut G, Botar-Jid C,
Vasilescu D, Bojan A and Dudea SM: Ultrasonographic identification
of the anatomical landmarks that define cervical lymph nodes
spaces. Med Ultrason. 15:29–34. 2013.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Emmenegger U, Reimers A and Frey U:
Reactive macrophage activation syndrome: A simple screening
strategy and its potential in early treatment initiation. Swiss Med
Wkly. 132:230–236. 2002.PubMed/NCBI
|
|
59
|
Ramanan AV, Akikusa JD, Silverman ED and
Schneider R: Extreme hyperferitinemia in childhood. Clin Exp
Rheumatol. 21:55–59. 2003.
|
|
60
|
Gorelik M, Fall N, Altaye M, Barnes MG,
Thompson SD, Grom AA and Hirsch R: Follistatin-like protein 1 and
the ferritin/erythrocyte sedimentation rate ratio are potential
biomarkers for dysregulated gene expression and macrophage
activation syndrome in systemic juvenile idiopathic arthritis. J
Rheumatol. 40:1191–1199. 2013.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Emmenegger U, Frey U and Reimers A:
Hyperferritinemia as indicator for intravenous immunoglobulin
treatment in reactive macrophage activation syndromes. Am J
Hematol. 68:4–10. 2001.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Orasan OH, Iancu M, Sava M, Saplontai-Pop
A, Cozma A, Sarlea ST, Lungoci C, Ungureanu MI, Negrean V,
Sampelean D and Dumitrascu DL: Non-invasive assessment of liver
fibrosis in chronic viral hepatitis. Eur J Clin Invest.
45:1243–1251. 2015.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Davi S, Consolaro A, Guseinova D, Pistorio
A, Ruperto N, Martini A, Cron RQ and Ravelli A: MAS Study Group. An
international consensus survey of diagnostic criteria for
macrophage activation syndrome in systemic juvenile idiopathic
arthritis. J Rheumatol. 38:764–768. 2011.PubMed/NCBI View Article : Google Scholar
|
